Molybdenum Trioxide Nanocubes Aligned on a Graphene Oxide Substrate for the Detection of Norovirus by Surface-Enhanced Raman Scattering
Molybdenum Trioxide Nanocubes Aligned on a Graphene Oxide Substrate for the Detection of Norovirus by Surface-Enhanced Raman Scattering
复制标题
DOI：
10.1021/acsami.0c14729
复制
发表时间：
2020-09-30
影响因子：
9.5
通讯作者：
Park, Enoch Y.
中科院分区：
文献类型：
--
作者：
Achadu, Ojodomo J.;Abe, Fuyuki;Park, Enoch Y.
基于石墨烯介导的表面增强拉曼散射（G-SERS）技术，设计了一种基于等离子体/磁性三氧化钼纳米立方体（mag-MoO 3 NCs）的新型生物传感系统，通过双Sers纳米标签/基底平台检测诺如病毒（NoV）。一种新型的磁性MoO 3纳米颗粒衍生物作为Sers纳米标签和生物传感器的免疫磁性分离材料。采用单层氧化石墨烯（SLGO）作为2D Sers基底/捕获平台并充当信号报告子，具有容纳额外的拉曼分子作为共报告子的能力。所开发的基于SERS的免疫测定实现了高达10（9）倍的信号放大，这是由双Sers纳米标签/基底系统的电磁和化学机制的组合产生的。所开发的生物传感器被用于检测从感染患者收集的人类粪便样品中的NoV，通过捕获病毒与援助的NoV特异性抗体功能化的磁性MoO 3 NC。这种方法使得能够利用这种生物传感技术进行NoV检测的快速信号放大。使用NoV样颗粒在10 fg/mL至100 ng/mL的宽线性范围内和类似于5.2 fg/mL的检测限（LOD）对生物传感器进行测试和优化。所开发的生物传感器检测人粪便样品中临床NoV亚型的实用性通过有效检测得到证明，LOD类似于60 RNA拷贝/mL，这比NoV的商业酶联免疫吸附测定试剂盒低10（3）倍。
A novel biosensing system based on graphene-mediated surface-enhanced Raman scattering (G-SERS) using plasmonic/magnetic molybdenum trioxide nanocubes (mag-MoO3 NCs) has been designed to detect norovirus (NoV) via a dual SERS nanotag/substrate platform. A novel magnetic derivative of MoO3 NCs served as the SERS nanotag and the immunomagnetic separation material of the biosensor. Single-layer graphene oxide (SLGO) was adopted as the 2D SERS substrate/capture platform and acted as the signal reporter, with the ability to accommodate an additional Raman molecule as a coreporter. The developed SERS-based immunoassay achieved a signal amplification of up to similar to 10(9)-fold resulting from the combined electromagnetic and chemical mechanisms of the dual SERS nanotag/substrate system. The developed biosensor was employed for the detection of NoV in human fecal samples collected from infected patients by capturing the virus with the aid of NoV-specific antibody-functionalized magnetic MoO3 NCs. This approach enabled rapid signal amplification for NoV detection with this biosensing technology. The biosensor was tested and optimized using NoV-like particles within a broad linear range from 10 fg/mL to 100 ng/mL and a limit of detection (LOD) of similar to 5.2 fg/mL. The practical applicability of the developed biosensor to detect clinical NoV subtypes in human fecal samples was demonstrated by effective detection with an LOD of similar to 60 RNA copies/mL, which is similar to 10(3)-fold lower than that of a commercial enzyme-linked immunosorbent assay kit for NoV.